your market intelligence analyst
Search Results
27 results
Your search is now limited to «Excipients» expert search.
In Article 2(a) it is specified that “residues of pharmacologically actives substances” means all pharmacologically active substances, expressed in mg/kg or μg/kg on a fresh weight basis, whether active substances, excipients or degradation products, and their metabolites which remain in food obtained from animals.
Vascular News 10/16/2019 04:27
Philips has received US Food and Drug Administration (FDA) approval for two Stellarex 0.035” low-dose (200mm and 150mm) drug-coated balloons for the treatment of de novo and restenotic lesions in native superficial femoral or popliteal arteries. According to a press release, the new balloons broaden physicians’ treatment options for peripheral artery disease (PAD) patients with […]. .
Vascular News 10/15/2019 11:23
It was recently announced that luminor 18 and luminor 35 DCBs (iVascular), are now listed on the French LPPR list for de novo lesions of the femoro-popliteal arteries. Luminor is a paclitaxel coated balloon specifically designed for dilatation of stenosis located in the iliac, femoral, iliofemoral, popliteal, infrapopliteal and renal arteries, as well as for […]. .

Personal Care

Household Products

Business Issues


Companies - Public

Companies - Venture Funded

Information Technologies


Job Titles